Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Anti-interleukin-1 therapy in rheumatic diseases
Autore:
Dayer, JM; Feige, U; Edwards, CK; Burger, D;
Indirizzi:
Univ Hosp Geneva, Div Immunol & Allergy, CH-1211 Geneva 14, Switzerland Univ Hosp Geneva Geneva Switzerland 14 y, CH-1211 Geneva 14, Switzerland Amgen Inc, Dept Pharmacol, Thousand Oaks, CA 91320 USA Amgen Inc ThousandOaks CA USA 91320 armacol, Thousand Oaks, CA 91320 USA Amgen Inc, Dept Inflammat Res, Thousand Oaks, CA 91320 USA Amgen Inc Thousand Oaks CA USA 91320 mat Res, Thousand Oaks, CA 91320 USA
Titolo Testata:
CURRENT OPINION IN RHEUMATOLOGY
fascicolo: 3, volume: 13, anno: 2001,
pagine: 170 - 176
SICI:
1040-8711(200105)13:3<170:ATIRD>2.0.ZU;2-F
Fonte:
ISI
Lingua:
ENG
Soggetto:
INTERLEUKIN-1 RECEPTOR ANTAGONIST; COLLAGEN-INDUCED ARTHRITIS; NECROSIS-FACTOR-ALPHA; CARTILAGE PROTEOGLYCAN LOSS; ANTIGEN-INDUCED ARTHRITIS; STIMULATED T-LYMPHOCYTES; FACTOR-BINDING-PROTEIN; HUMAN-MONOCYTES; SOLUBLE CD23; TNF-ALPHA;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
70
Recensione:
Indirizzi per estratti:
Indirizzo: Dayer, JM Univ Hosp Geneva, Div Immunol & Allergy, CH-1211 Geneva 14, Switzerland Univ Hosp Geneva Geneva Switzerland 14 Geneva 14, Switzerland
Citazione:
J.M. Dayer et al., "Anti-interleukin-1 therapy in rheumatic diseases", CURR OP RH, 13(3), 2001, pp. 170-176

Abstract

Recent research has shown that in the processes of rheumatoid arthritis (RA), interleukin (IL)-1 is one of the pivotal cytokines in initiating disease, and the body's natural response, IL-l receptor antagonist (IL-l Ra), hasbeen shown conclusively to block its effects. In laboratory and animal studies inhibition of IL-l by either antibodies to IL-l or IL-l Ra proved beneficial to the outcome. To date, two large well-controlled studies in patients with RA led to the conclusion that IL-l Ra is clinically effective and that it slows progression of bone damage as measured radiographically. Beinga specific, selective inhibitor of the IL-l pathway, IL-l Ra could constitute an important new approach to treating patients with RA that significantly reduces the signs and symptoms of the disease, reduces joint destructionand up to now has proved Safe and well tolerated. (C) 2001 Lippincott Williams & Wilkins, Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/12/20 alle ore 22:13:33